Trials / Recruiting
RecruitingNCT07318675
A Phase Ib Study of HW211026 Ointment in Patients With Actinic Keratosis.
A Randomized, Double-Blind, Placebo-Controlled, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HW211026 Ointment After Single or Multiple Doses in Subjects With Actinic Keratosis
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase Ib study to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) characteristics of HW211026 ointment after single or multiple topical administrations in patients with actinic keratosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HW211026 | Dose 1 and Dose 2 |
| DRUG | Placebo | Dose 1 and Dose 2 |
Timeline
- Start date
- 2025-12-25
- Primary completion
- 2026-03-01
- Completion
- 2026-03-01
- First posted
- 2026-01-06
- Last updated
- 2026-01-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07318675. Inclusion in this directory is not an endorsement.